Features and consequences of untreated type 1 autoimmune hepatitis

Liver International

Volumn 29, Issue 6, 2009, Pages 816-823

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Asymptomatic; Autoimmune hepatitis; Mild disease; Treatment criteria

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DIURETIC AGENT; PREDNISONE;

ADULT; ARTICLE; ASCITES; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MORTALITY; NECROSIS; OSTEOPENIA; PATIENT SATISFACTION; PROGNOSIS; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SODIUM RESTRICTION; TREATMENT FAILURE; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 59649086033     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01904.x     Document Type: Article

References (46)

1. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
2. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
3. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
4. Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1972; 63: 458-65.
5. Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972; 3: 183-98.
6. Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973-80.
7. Cooksley WGE, Bradbear RA, Robinson W, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986; 6: 345-8.
8. Koretz RL, Lewin KJ, Higgins J, Fagen ND, Gitnick GL. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980; 25: 695-9.
9. Hodges JR, Millward-Sadler GH, Wright R. Chronic active hepatitis: The spectrum of disease. Lancet 1982; 1: 550-2.
10. Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg negative chronic active hepatitis. J Hepatol 1992; 14: 88-93.
11. Czaja AJ, Bianchi FB, Carpenter HA, et al. Report of the International Autoimmune Hepatitis Group. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-15.
12. Czaja AJ, Freese DK. AASLD treatment guidelines. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
13. DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-3.
14. Thaler H. The natural history of chronic hepatitis. In: Schaffner F, Sherlock S, Leevy CM, eds. The Liver and its Diseases. New York: Stratton International Medical Books, 1974; 207-15.
15. Fevery J, Desmet VJ, DeGroote J. Long-term follow-up and management of asymptomatic chronic active hepatitis. In: Cohen S, Soloway RD, eds. Chronic Active Liver Disease. New York: Churchill Livingstone, 1983; 51-64.
16. Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Aust Ann Med 1968; 17: 214-23.
17. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7: 319-33.
18. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81.
19. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
20. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 541-7.
21. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
22. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73.
23. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997; 42: 1688-96.
24. Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122: 993-9.
25. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.
26. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: A point of view. Am J Gastroenterol 1995; 90: 1206-11.
27. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32.
28. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WHJ. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1975; 20: 1087-90.
29. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-8.
30. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007; 5: 898-907.
31. Montano Loza A, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 202-14.
32. Montano-Loza A, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
33. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): Correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
34. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6: 799-824.
35. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology 2007; 46: 1138-45.
36. Terasaki P, Mcclelland JD, Park MS, Mccurdy B. Microdroplet lymphocyte cytotoxicity test. In: DHEW Publication (N.I.H.) 74-545. Manual of Tissue Typing Techniques. Washington, DC: US Government Printing Office, 1973; 54-61.
37. Czaja AJ, Rakela J, Hay JE, Moore SB. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1990; 98: 1587-93.
38. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
39. Mytilineos J, Scherer S, Opelz G. Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals. Transplantation 1990; 50: 870-3.
40. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
42. Peto R, Pike MC. Conservatism of the approximation (0-E)/E in the log rank test for survival data on tumor incidence data. Biometrics 1973; 29: 579-84.
43. Donaldson PT, Doherty DG, Hayllar KM, Mcfarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6.
44. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 644-50.
45. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
46. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/ liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.